Background-Prior studies demonstrate a direct relationship between treatment delays to primary percutaneous intervention and mortality in patients with ST-segment elevation myocardial infarction (STEMI). This analysis compared the relationship of symptom onset-to-balloon time and door-to-balloon time on mortality in patients with STEMI. Methods and Results-We analyzed different treatment delays (symptom onset-to-balloon time, door-to-balloon time) and mortality in 5745 STEMI patients. Baseline characteristics, flow grade, 90-day mortality, and clinical outcomes were compared in patients stratified by treatment delay. Multivariable logistic regression modeling was performed to assess the independent and relative effect of each treatment delay on 90-day mortality. Female sex, increased age, and worse thrombolysis in myocardial infarction flow grade were significantly associated with longer symptom onset-to-balloon times and door-to-balloon times. Longer symptom onset-to-balloon time was significantly associated with worse 90-day mortality (3.7%, 4.2%, and 6.5% for time delays Ͻ3 hours, 3 to 5 hours, and Ͼ5 hours, respectively, PϽ0.0001).
tery using fibrinolysis or primary percutaneous coronary intervention (PCI) reduces infarct size, decreases morbidity, and increases survival in patients with ST-segment elevation myocardial infarction (STEMI). 1, 2 Compared with fibrinolytic therapy, primary PCI establishes Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 in 80% to 95% of patients, significantly lowers the risk of intracranial hemorrhage, and offers more robust survival advantage in higherrisk patients with cardiogenic shock, severe heart failure, or unstable arrhythmias. 2, 3 Multiple randomized clinical studies also have demonstrated the superiority of rapid primary PCI over fibrinolysis in STEMI. 4 Thus, both the American College of Cardiology/American Heart Association and European Society of Cardiology STEMI guidelines recommend primary PCI as the preferred management strategy of STEMI over pharmacological reperfusion in experienced centers capable of performing primary PCI within 90 minutes of initial medical contact. 3, 5 Despite this recommendation, achieving primary PCI within 90 minutes has proven to be an elusive goalespecially for patients presenting to hospitals without PCI capability. Although some studies have suggested that time to reperfusion is less important for PCI than fibrinolysis, 6, 7 most studies have demonstrated that treatment delays to primary PCI are associated with increased mortality 8 -13 and larger infarct size. 14 Prior studies, however, differ on whether the total ischemic interval between symptom onset and PCI reperfusion, so-called symptom-to-balloon (STB) time best predicts mortality, or whether mortality is more strongly determined by the duration between hospital arrival and performance of primary angioplasty, the so-called door-toballoon (DTB) time.
To address this issue and better characterize the mortality impact of treatment delays, both DTB time and STB time, we used detailed patient data from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) Trial. 15 
WHAT IS KNOWN
• Primary percutaneous coronary intervention (PCI) reperfusion delays for patients with ST-elevation myocardial infarction are associated with increased mortality. • Prior studies differ on whether patient total ischemic time (symptom onset-to-balloon) or hospital "doorto-balloon" time more strongly predict mortality.
WHAT THE STUDY ADDS
• Advanced age, female sex, and interhospital transfer are important determinants of primary PCI reperfusion delays. • Both symptom onset-to-balloon time and hospital door-to-balloon time are strongly associated with 90-day mortality following ST-elevation myocardial infarction. • Mortality following ST-elevation myocardial infarction rises sharply with symptom onset-to-balloon delays exceeding 5 hours and linearly with any door-to-balloon delay.
Methods

Study Population
Between 
Study Design and Statistical Analysis
Study coordinators and investigators collected and submitted detailed data during the APEX AMI Trial related to baseline clinical/ demographic characteristics, treatment delays, hospital complica- 16 ST-segment recovery was calculated by ⌺ST-deviation recovery (percentage reduction in ⌺ST deviation from baseline to post-PCI ECG) analyzed by mean value and 3 categories (Ն70%, 30% to 70%, Ͻ30%). 17 Post-PCI epicardial artery patency and flow was determined by a local cardiologist and categorized according to Thrombolysis and Myocardial Infarction Investigator flow grades. 18 An investigation of contemporary STEMI treatment delays and their impact on mortality outcomes was planned at the inception of the APEX AMI trial. All data entries regarding time of symptom onset, hospital presentation, and primary PCI were determined and entered prospectively during the trial. The time of symptom onset was estimated from direct patient interviews or obtained from physician entries in the emergency department and medical record. Time of hospital arrival was defined as the time a patient presented to the initial care facility and was determined by ambulance, emergency department, and ECG documentation sources. For patients undergoing interhospital transfer, hospital arrival commenced at the initial hospital arrival and DTB time included transfer duration between facilities. Timing of reperfusion therapy was defined as the time of initial balloon inflation in the infarct-related artery as determined directly by coordinators or from catheterization reports. In this analysis, we primarily analyzed and compared clinical characteristics and outcomes related to 2 important treatment intervals-specifically, the duration of time between hospital arrival and infarct artery balloon inflation-DTB time and the cumulative duration between estimated symptom onset and infarct artery balloon inflation (STB) time.
In this analysis, we categorized STB and DTB intervals as (Ͻ3 hours, 3 to 5 hours, and Ͼ5 hours) and (Ͻ60 minutes, 60 to 90 minutes, 90 to 120 minutes, and Ն120 minutes), respectively. Baseline and clinical characteristics were compared between STB and DTB patient groups by 2 , analysis of variance, and Wilcoxon rank-sum test. Clinical outcomes of 30-day all-cause mortality and 90-day all-cause mortality were reported in 99.7% of patients with missing 90-day survival status in only 15 patients. Congestive heart failure and cardiogenic shock end points were defined in the APEX 
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AMI publication 15 and centrally adjudicated by a clinical events committee. Statistical assessment of DTB and STB differences in 30-day mortality, heart failure and cardiogenic shock was performed using 2-sided 2 test. Survival analysis was used to assess differences in 90-day mortality for STB and DTB strata and a Cox proportional hazards model developed for 90-day mortality. Ninetyday mortality differences were descriptively summarized as adjusted hazard ratios with associated confidence intervals. Log-rank statistic was used to compare overall survival distribution between STB and DTB groups. The Cox proportional hazards model included independent variables of age, systolic blood pressure, heart rate, Killip class III/IV, prior diabetes, total ST-segment deviation, and anterior infarct location, along with STB and DTB. Transformations for continuous variables were assessed to meet modeling assumptions. Heart rate and time from symptom onset to balloon were not linearly related to outcome; hence, a transformation was necessary. The slope for presenting heart rate changed at 70 beats/min. As a result, the heart rate was modeled with one slope between 30 and 70 beats/min and another slope for heart rate Ͼ70 beats/min. Time from symptom onset (STB) was similar with need for a change in slope occurring before and after 3.3 hours. These variables then did meet the modeling assumption of linearity. Baseline creatinine values Յ90 mol/L were not informative and were set to 90 mol/L, whereas higher creatinine measurements were modeled linearly. Ninety-day mortality survival function is displayed graphically versus independent variables of DTB time (see Figure 3 ) and STB time (see Figure 4 ) using PROC LIFETEST procedure. Adjusted SAS version 8.2 software (SAS Institute Inc., Cary, NC) was used to conduct all statistical analysis.
Results
Baseline Characteristics
Among 5745 patients enrolled in the APEX AMI trial, 370 patients (6.4%) had indeterminate time of symptom onset, hospital arrival, or infarct-artery balloon inflation, and were therefore excluded from this analysis. Tables 1 and 2 show baseline and clinical characteristics for the remaining 5375 patients according to STB and DTB categories. Increased age 
Angiographic and ST Recovery Outcomes
In total, 90.0% (4973/5527) of APEX AMI patients achieved TIMI flow grade 3 in the infarct-artery following primary PCI. As shown in Tables 1 and 2, worse (lower) TIMI flow grade was associated with longer STB and DTB times. The proportion of patients achieving TIMI grade 3 flow at completion of PCI was significantly reduced as STB and DTB times increased (Figure 1) . Similarly, mean cumulative ST resolution was significantly increased in patients with the shortest STB and DTB times ( Tables 1 and 2 ).
Clinical Outcomes/Mortality
Ninety-day all-cause mortality results along with 30-day mortality and prespecified outcomes of congestive heart failure and shock according to DTB and STB are shown in Table 3 . There were stepwise and progressive increases in 30-day and 90-day mortality ( Figure 2 ) along with increased incidence of cardiogenic shock and composite adverse outcomes with increasing STB and DTB intervals. Ninety-day mortality rates are plotted versus DTB and STB delays in Figures 3 and 4 , respectively. This relationship is relatively linear across the range of DTB times (0 to 180 minutes) encountered in the APEX AMI trial. Conversely, 90-day mortality was only modestly impacted by increased STB delays Ͻ5 hours, but rose precipitously thereafter as STB times further increased beyond 300 minutes. Ninety-day mortality was 3.3% (95% CI 2.5, 4.4) in patients with STB times of 3 to 4 hours, 5.5% (95% CI 4.2, 7.2) in patients with STB times of 4 to 5 hours, and 6.5% (95% CI 5.1, 8.2) in patients with STB times of Ͼ5 hours. The interrelationship of STB and DTB with each other and their additive impact on 90-day mortality are displayed in Figure 5 . Additionally, unadjusted rates of 90-day mortality are shown across various STEMI patient subgroups (Table 4 ) demonstrating positive mortality association with both STB and DTB delays. 
Multivariable Mortality Model
Discussion
STEMI Treatment Delays
The APEX AMI study was the largest, contemporary randomized primary PCI trial ever conducted and is generalizable to current global primary PCI practice. The study included patients from 296 hospitals in 17 countries throughout North America, Europe, and Australia. Inclusion criteria limited enrollment to STEMI patients and patients who received treatment in a reasonably timely fashion with median DTB times of 1.6 hours (interquartile range, 1.08 to 2.22 hours). Despite current STEMI guidelines 3, 5 and public health emphasis on primary PCI treatment times, Ͼ60% of study patients had STB times exceeding 3 hours and 56% had DTB times exceeding 90 minutes. Consistent with prior studies, 19, 20 advanced age and female sex were major demographic factors associated with both prolonged STB and DTB times in our study. Median DTB time was longer, whereas median symptom onset-to-hospital arrival time was shorter in patients enrolled in the United States. Additional factors associated with prolonged STB times (absence of chest pain, comorbidities) and prolonged DTB times (hospital type, size, STEMI case volume) were not analyzed. 21 However, our data do suggest that hospital presentation during weekends or weekday "off-hours" (6 PM to 6 AM) was significantly associated with prolonged DTB times. A future APEX AMI analysis will examine the impact of interhospital transfer on PCI delays and outcomes.
Primary PCI Delays and Mortality
Strong, consistent data link DTB delays and increased mortality. Berger et al 7 demonstrated in the GUSTO-IIb study that 30-day mortality was lowest in STEMI patients treated within 60 minutes of study enrollment and rose progressively with hospital delays to first balloon inflation. National Registry of Myocardial Infarction 2 observational data showed that hospital mortality did not increase significantly with increasing delay from symptom onset to PCI, whereas DTB times Ͼ120 minutes were strongly associated with worse survival. 5 National Registry of Myocardial Infarction 3 and 4 data of 29 222 STEMI patients associate longer DTB times with increased in-hospital mortality (3.0%, 4.2%, 5.7%, and 7.4% for DTB times of Յ90 minutes, 91 to 120 minutes, 121 to 150 minutes, and Ͼ150 minutes, respectively; PϽ0.01). 10 Importantly, this association of increased mortality with DTB time was seen regardless of symptom onset-to-door time and regardless of the presence or absence of high-risk clinical factors. Additional meta-analysis data suggest that major adverse cardiac events increase with prolonged time to hospital presentation in patients receiving fibrinolysis, but that prolonged STB times minimally influence infarct artery patency or survival outcomes following primary PCI. 6 The above data have focused most primary PCI quality improvement efforts toward reducing DTB times. 22, 23 Still, other studies have highlighted the importance of STB times on STEMI outcomes. Brody et al 12, 13 have shown that earlier primary PCI reperfusion from symptom onset (Ͻ3 hours versus 3 to 6 hours versus Ͼ6 hours) results in superior clinical outcomes, enhanced microvascular reperfusion, better recovery of left ventricular function, and lower 1-year mortality (2.6% versus 4.3% versus 4.8%, Pϭ0.05). Similarly, Sheiban and colleagues have demonstrated that STB times Ͻ4 hours are associated with substantial recovery of left ventricular systolic function. 24 De Luca and the ZWOLLE Myocardial Infarction Study Group have shown in 1791 patients with STEMI treated with primary PCI, that STB and not DTB is related to post-STEMI mortality. 8 In their STEMI cohort, STB time Ͼ4 hours was identified as independent predictor of 1-year mortality. These same investigators adjusted for age, sex, diabetes, and previous revascularization and determined that each 30 minutes of STB delay is associated with a relative risk for 1-year mortality of 1.075 (95% CI [1.008, 1.15], Pϭ0.04). 9
Conclusions
We have shown that both STB and DTB times are associated with post-PCI TIMI flow grade, ST-segment recovery, the incidence of cardiogenic shock, and both 30-day and 90-day mortality. Comparing STB (Ͻ3 hours, 3 to 5 hours, and Ͼ5 hours) and DTB strata (Ͻ60 minutes, 60 to 90 minutes, 90 to 120 minutes, and Ն120 minutes), we have shown statistically significant and progressively worse mortality for every STB or DTB delay. Importantly, we have shown that mortality increases progressively with DTB times from 0 to 180 minutes, and STB times Ͼ5 hours are progressively associated with increased mortality. In a multivariate mortality model, we have compared the effect of DTB delays versus symptom onset-to-hospital presentation time and would conclude that prehospital delays, and likely total ischemic time, are statistically more significantly associated with survival than DTB delays.
Study Limitations
These data and associations are derived from the contemporary APEX AMI trial and may not be generalizable to all STEMI patients. Importantly, the APEX AMI trial investigated only primary PCI, not fibrinolytic therapy, and limited enrollment to patients with symptom duration Յ6 hours. Treatment delay implications in patients presenting Ͼ6 hours following symptoms or receiving fibrinolytic therapy may differ. Additionally, angiographic reperfusion data (TIMI flow grade) was locally determined by interventional cardiologists and not evaluated or adjudicated by an angiographic core laboratory.
Clinical Implications
Contemporary reperfusion strategies, published STEMI guidelines, and STEMI quality initiatives all aim to reduce primary PCI delays and improve patient outcomes. Our data reinforce these initiatives and encourage efforts to reduce total ischemic time in STEMI patients both before and after hospital arrival with particular attention and interventions devoted to female, elderly, and transfer patients.
